Key Highlights
- 12.04% is the intraday decline to USD 9.97 for SELLAS Life Sciences (NASDAQ:SLS) per published market data (October 16, 2026 intraday). The gap was -1.25% and the move from the open was -11.34%, on 2,911,336 shares, 0.7x the average volume.
- 78 of 80 is the last reported event count in the Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia, per published reports dated July and October 2026. The August 11, 2026 release said SELLAS is approaching the 80th event, which triggers database lock and unblinding.
- USD 138.3 million is cash and cash equivalents at June 30, 2026, up from USD 71.8 million at December 31, 2025, per the August 11, 2026 8-K. Q2 net loss was USD 9.6 million, or USD 0.05 per share, against USD 6.6 million a year earlier.
- USD 29.0 million is dollar turnover at USD 9.97 (own arithmetic), or 1.44% of the USD 2.01 billion market capitalisation. The stock closed at USD 12.31 on September 30, 2026, so it has lost 19.0% since then (own arithmetic on two published quotes).
Price Action and Catalyst Review
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026, although the table labels the session as News with a question mark. Published market data show USD 9.97, down 12.04% from an implied prior close of USD 11.34 (own arithmetic). The gap of -1.25% set the open at USD 11.19, and the stock then fell 11.34% from the open, so most of the decline occurred during the session, not at the open.
Liquidity and Trading Activity
Relative volume of 0.7x implies an average of 4.16 million shares (own arithmetic), so the label of unusual volume is not supported: the session ranks below average. Market capitalisation divided by price gives 201.6 million shares (own arithmetic). Published market data from mid-July 2026 put short interest at 32.33% of the float, with 4.75 days to cover. Heavy short positioning and a pending binary readout mean that positioning changes can move the price without any announcement.
Capital Structure and Readout Risks
Cash rose USD 66.5 million in the first half of 2026 despite an USD 18.0 million net loss (own arithmetic on two filings), which implies at least that amount of financing inflow through share sales or warrant exercises, each of which dilutes holders. A USD 150 million at-the-market program with TD Cowen was reported; its terms were not reviewed. Q2 operating expense was USD 10.7 million, so USD 138.3 million covers 43 months at the Q2 net loss rate (own arithmetic). SLS009 frontline AML topline data are expected in Q4 2026, and 28 of 80 patients were enrolled in August.
Where Things Stand
The decline is not explained by any filing reviewed, so the answer is that it reflects positioning ahead of a binary event rather than news. SELLAS Life Sciences (NASDAQ:SLS) fell 12.04% on 0.7x average volume while REGAL stands at a reported 78 of 80 events. A positive final analysis could support an FDA submission, and a negative one would remove the lead asset, so the distribution of outcomes is wide. Cash of USD 138.3 million limits near-term financing pressure. The next dated catalyst is the 80th event announcement, which has no confirmed date.






Please wait processing your request...